Search results for " Digestive diseases"
showing 2 items of 2 documents
White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths
2014
In 2011 the three major Italian gastroenterological scientific societies (AIGO, the Italian Society of Hospital Gastroenterologists and Endoscopists; SIED, the Italian Society of Endoscopy; SIGE, the Italian Society of Gastroenterology) prepared their official document aimed at analysing medical care for digestive diseases in Italy, on the basis of national and regional data (Health Ministry and Lombardia, Veneto, Emilia-Romagna databases) and to make proposals for planning of care. Digestive diseases were the first or second cause of hospitalizations in Italy in 1999–2009, with more than 1,500,000 admissions/year; however only 5–9% of these admissions was in specialized Gastroenterology un…
MaleGastrointestinal DiseasesTreatment outcomeDiseasesMedical careGastroenterologyCancer; Digestive diseases; Emergency; Gastroenterology; Gastrointestinal bleeding; Hospital discharge record; Hospital stay; Mortality; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Emergencies; Female; Gastroenterology; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Health Planning; Health Services; Health Services Needs and Demand; Hospital Mortality; Hospital Units; Humans; Incidence; Infant; Infant Newborn; Italy; Length of Stay; Male; Middle Aged; Prevalence; Societies Medical; Treatment Outcome; Young AdultHealth servicesWhite paperDigestive diseaseitaly80 and overPrevalenceMedicineCancer; Digestive diseases; Emergency; Gastroenterology; Gastrointestinal bleeding; Hospital discharge record; Hospital stay; Mortality; Adolescent; Adult; Aged; Aged 80 and over; Child; Child Preschool; Emergencies; Female; Gastroenterology; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Health Planning; Health Services; Health Services Needs and Demand; Hospital Mortality; Hospital Units; Humans; Incidence; Infant; Infant Newborn; Italy; Length of Stay; Male; Middle Aged; Prevalence; Societies Medical; Treatment Outcome; Young Adult; Hepatology; GastroenterologyHospital MortalityChildSocieties MedicalCancerAged 80 and overSettore MED/12 - GastroenterologiaHospital stayIncidenceIncidence (epidemiology)GastroenterologyHealth ServicesMiddle AgedDigestive diseases Emergency Gastroenterology Gastrointestinal bleeding Hospital discharge record Hospital stay MortalityTreatment OutcomeChild PreschoolFemaleChristian ministryGastrointestinal HemorrhageHospital UnitsHospital discharge recordAdultgastroenterology; Diseases; italymedicine.medical_specialtyAdolescentYoung AdultCase mix indexMedicalInternal medicineHumansCancer Digestive diseases Emergency Gastroenterology Gastrointestinal bleeding Hospital discharge record Hospital stay MortalityMortalityPreschoolGastrointestinal bleedingAgedHealth Services Needs and DemandHepatologybusiness.industryInfant NewbornInfantLength of StayHepatologyNewbornHealth PlanningEmergencyDigestive diseasesEmergenciesSocietiesbusinessDigestive and Liver Disease
researchProduct
Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
2022
Funder: European Commission
ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct